Seattle Genetics Reports Final Non-Hodgkin Lymphoma Findings

Seattle Genetics documented final data from its Phase I clinical trial of SGN-40 in patients with relapsed or refractory non-Hodgkin lymphoma.

The drug is a humanized, monoclonal antibody being developed in collaboration with Genentech.

It achieved multiple objective responses in a study of 50 patients. It was generally well tolerated with no maximum tolerated dose identified, Seattle Genetics said.